Similar findings have been reported with ruxolitinib treatment in patients with MF.28 TNF-α can facilitate expansion of the JAK2V617F clone,29 an activating mutation that can ultimately drive splenomegaly. This evidence concerns the gene TNF and Splenomegaly.